BRAF and colorectal cancer: Despite therapeutic advances, BRAFV600E-mutant metastatic melanoma develops resistance to BRAFV600E inhibitors after initially responding (4, 5), and colorectal cancers are often intrinsically resistant to BRAF kinase inhibitors, underscoring the need to identify potential routes of drug resistance and new targets for these resistant malignancies (6, 7).